166 related articles for article (PubMed ID: 7499842)
21. Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy.
Neeley YC; Arredouani MS; Hollenbeck B; Eng MH; Rubin MA; Sanda MG
Prostate; 2008 May; 68(7):715-27. PubMed ID: 18302222
[TBL] [Abstract][Full Text] [Related]
22. Development of a transgenic mouse system for the analysis of stages in liver carcinogenesis using tissue-specific expression of SV40 large T-antigen controlled by regulatory elements of the human alpha-1-antitrypsin gene.
Sepulveda AR; Finegold MJ; Smith B; Slagle BL; DeMayo JL; Shen RF; Woo SL; Butel JS
Cancer Res; 1989 Nov; 49(21):6108-17. PubMed ID: 2551499
[TBL] [Abstract][Full Text] [Related]
23. Increased threshold for TCR-mediated signaling controls self reactivity of intraepithelial lymphocytes.
Guehler SR; Finch RJ; Bluestone JA; Barrett TA
J Immunol; 1998 Jun; 160(11):5341-6. PubMed ID: 9605133
[TBL] [Abstract][Full Text] [Related]
24. Tolerant CD8 T cells induced by multiple injections of peptide antigen show impaired TCR signaling and altered proliferative responses in vitro and in vivo.
Dubois PM; Pihlgren M; Tomkowiak M; Van Mechelen M; Marvel J
J Immunol; 1998 Nov; 161(10):5260-7. PubMed ID: 9820498
[TBL] [Abstract][Full Text] [Related]
25. A self-reactive class I-restricted T-cell response of H-2b mice to determinants of the V beta 8.2 domain of the T-cell receptor for antigen.
Kuhröber A; Schirmbeck R; Reimann J
Immunology; 1994 Dec; 83(4):532-9. PubMed ID: 7533132
[TBL] [Abstract][Full Text] [Related]
26. Self-peptides that bind with low affinity to the diabetes-associated I-A(g7) molecule readily induce T cell tolerance in non-obese diabetic mice.
Ferlin WG; Mougneau E; Hugues S; Appel H; Jang MH; Cazareth J; Beaudoin L; Schricke C; Lehuen A; Wucherpfennig KW; Glaichenhaus N
Eur J Immunol; 2004 Oct; 34(10):2656-63. PubMed ID: 15368281
[TBL] [Abstract][Full Text] [Related]
27. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
28. I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice.
Noorchashm H; Lieu YK; Noorchashm N; Rostami SY; Greeley SA; Schlachterman A; Song HK; Noto LE; Jevnikar AM; Barker CF; Naji A
J Immunol; 1999 Jul; 163(2):743-50. PubMed ID: 10395666
[TBL] [Abstract][Full Text] [Related]
29. Prevention of autoimmune disease by retroviral-mediated gene therapy.
Ally BA; Hawley TS; McKall-Faienza KJ; Kündig TM; Oehen SU; Pircher H; Hawley RG; Ohashi PS
J Immunol; 1995 Dec; 155(11):5404-8. PubMed ID: 7594557
[TBL] [Abstract][Full Text] [Related]
30. T cell tolerance and autoimmunity.
Abbas AK; Lohr J; Knoechel B; Nagabhushanam V
Autoimmun Rev; 2004 Nov; 3(7-8):471-5. PubMed ID: 15546793
[TBL] [Abstract][Full Text] [Related]
31. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.
Wirth S; Guidotti LG; Ando K; Schlicht HJ; Chisari FV
J Immunol; 1995 Mar; 154(5):2504-15. PubMed ID: 7868916
[TBL] [Abstract][Full Text] [Related]
32. An evaluation of mechanisms by which tolerance to organ-specific antigens is lost using a transgenic mouse model.
Martin L; Mora-Worms M; Lucas C; Reynolds C; Stewart TA
J Immunol; 1993 Feb; 150(4):1234-43. PubMed ID: 8432978
[TBL] [Abstract][Full Text] [Related]
33. V beta 5+ T cell receptors skew toward OVA+H-2Kb recognition.
Dillon SR; Jameson SC; Fink PJ
J Immunol; 1994 Feb; 152(4):1790-801. PubMed ID: 8120388
[TBL] [Abstract][Full Text] [Related]
34. Degenerate recognition of a dissimilar antigenic peptide by myelin basic protein-reactive T cells. Implications for thymic education and autoimmunity.
Bhardwaj V; Kumar V; Geysen HM; Sercarz EE
J Immunol; 1993 Nov; 151(9):5000-10. PubMed ID: 7691962
[TBL] [Abstract][Full Text] [Related]
35. The T lymphocyte response to cytochrome c. IV. Distinguishable sites on a peptide antigen which affect antigenic strength and memory.
Hansburg D; Fairwell T; Schwartz RH; Appella E
J Immunol; 1983 Jul; 131(1):319-24. PubMed ID: 6190913
[TBL] [Abstract][Full Text] [Related]
36. Non-tolerance and autoantibodies to a transgenic self antigen expressed in pancreatic beta cells.
Adams TE; Alpert S; Hanahan D
Nature; 1987 Jan 15-21; 325(6101):223-8. PubMed ID: 3543686
[TBL] [Abstract][Full Text] [Related]
37. In vivo imaging of an inducible oncogenic tumor antigen visualizes tumor progression and predicts CTL tolerance.
Buschow C; Charo J; Anders K; Loddenkemper C; Jukica A; Alsamah W; Perez C; Willimsky G; Blankenstein T
J Immunol; 2010 Mar; 184(6):2930-8. PubMed ID: 20142365
[TBL] [Abstract][Full Text] [Related]
38. Tissue-specific expression of allogeneic class II MHC molecules induces neither tissue rejection nor clonal inactivation of alloreactive T cells.
Miller J; Daitch L; Rath S; Selsing E
J Immunol; 1990 Jan; 144(1):334-41. PubMed ID: 2136884
[TBL] [Abstract][Full Text] [Related]
39. Detection of a complex of SV40 large tumor antigen and 53K cellular protein on the surface of SV40-transformed mouse cells.
Santos M; Butel JS
J Cell Biochem; 1982; 19(2):127-44. PubMed ID: 6294133
[TBL] [Abstract][Full Text] [Related]
40. SV40 large tumor antigen associated synthetic peptides define native antigenic determinants and induce protective tumor immunity in mice.
Bright RK; Shearer MH; Kennedy RC
Mol Immunol; 1994 Oct; 31(14):1077-87. PubMed ID: 7523865
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
